Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 7.5% – What’s Next?

Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) fell 7.5% during mid-day trading on Tuesday. The stock traded as low as $22.52 and last traded at $22.3630. Approximately 324,665 shares changed hands during mid-day trading, a decline of 91% from the average daily volume of 3,468,698 shares. The stock had previously closed at $24.17.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on TNGX shares. Wall Street Zen lowered Tango Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. HC Wainwright dropped their target price on Tango Therapeutics from $68.00 to $67.00 and set a “buy” rating on the stock in a research report on Tuesday, November 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tango Therapeutics in a research note on Wednesday, November 4th. Guggenheim boosted their price target on shares of Tango Therapeutics from $32.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Finally, Zacks Research lowered shares of Tango Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 27th. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $45.54.

Check Out Our Latest Report on Tango Therapeutics

Tango Therapeutics Stock Performance

The firm has a market capitalization of $3.77 billion, a P/E ratio of -16.26 and a beta of 1.26. The business has a fifty day moving average of $23.56 and a 200-day moving average of $22.86.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.04). On average, equities research analysts forecast that Tango Therapeutics, Inc. will post -1.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Adam Crystal sold 27,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $24.47, for a total value of $660,690.00. Following the completion of the transaction, the insider directly owned 115,743 shares in the company, valued at $2,832,231.21. This trade represents a 18.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jessica Newcomb sold 8,200 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $24.22, for a total value of $198,604.00. Following the sale, the insider directly owned 59,121 shares in the company, valued at approximately $1,431,910.62. The trade was a 12.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 52,231 shares of company stock worth $1,254,029 over the last three months. Corporate insiders own 6.50% of the company’s stock.

Hedge Funds Weigh In On Tango Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nykredit A S acquired a new position in shares of Tango Therapeutics during the 2nd quarter valued at $26,000. Allworth Financial LP bought a new position in Tango Therapeutics during the second quarter valued at about $35,000. Global Retirement Partners LLC bought a new position in Tango Therapeutics during the second quarter valued at about $122,000. Sterling Capital Management LLC grew its holdings in Tango Therapeutics by 838.8% during the third quarter. Sterling Capital Management LLC now owns 4,647 shares of the company’s stock worth $116,000 after acquiring an additional 4,152 shares during the period. Finally, ACT Capital Partners L.P. acquired a new position in Tango Therapeutics during the third quarter worth about $150,000. 78.99% of the stock is owned by institutional investors.

Tango Therapeutics Company Profile

(Get Free Report)

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.

Featured Stories

Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.